These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 2300386)

  • 1. Pharmacokinetics of intrapleural versus intravenous etoposide (VP 16) and teniposide (VM 26) in patients with malignant pleural effusion.
    Montaldo PG; Figoli F; Zanette ML; Sorio R; Zucchetti M; Tirelli U; D'Incalci M
    Oncology; 1990; 47(1):55-61. PubMed ID: 2300386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Podophyllotoxin derivatives VP-16 and VM-26.
    D'Incalci M; Garattini S
    Cancer Chemother Biol Response Modif; 1988; 10():57-63. PubMed ID: 3079398
    [No Abstract]   [Full Text] [Related]  

  • 3. Etoposide and teniposide. Bioanalysis, metabolism and clinical pharmacokinetics.
    Holthuis JJ
    Pharm Weekbl Sci; 1988 Jun; 10(3):101-16. PubMed ID: 3047665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of VM 26 given intrapericardially or intravenously in patients with malignant pericardial effusion.
    Figoli F; Zanette ML; Tirelli U; Sorio R; Lestuzzi C; Urso R; Monfardini S; D'Incalci M
    Cancer Chemother Pharmacol; 1987; 20(3):239-42. PubMed ID: 2824081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teniposide and etoposide in previously untreated small-cell lung cancer: a randomized study.
    Bork E; Ersbøll J; Dombernowsky P; Bergman B; Hansen M; Hansen HH
    J Clin Oncol; 1991 Sep; 9(9):1627-31. PubMed ID: 1651994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric cancer chemotherapy: an updated review. I. Cis-Diammine--dichloroplatinum II (cisplatin), VM-26 (teniposide), VP-16 (etoposide), mitomycin C.
    Gutierrez ML; Crooke ST
    Cancer Treat Rev; 1979 Sep; 6(3):153-64. PubMed ID: 394834
    [No Abstract]   [Full Text] [Related]  

  • 7. Intrapleural etoposide for malignant effusion.
    Holoye PY; Jeffries DG; Dhingra HM; Holmes FA; Raber M; Engineer MS; Newman RA
    Cancer Chemother Pharmacol; 1990; 26(2):147-50. PubMed ID: 2189591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VM 26 and VP 16-213: a comparative analysis.
    Rozencweig M; Von Hoff DD; Henney JE; Muggia FM
    Cancer; 1977 Jul; 40(1):334-42. PubMed ID: 328129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Podophyllotoxin derivatives VP-16 and VM-26.
    D'Incalci M; Garattini S
    Cancer Chemother Biol Response Modif; 1987; 9():67-70. PubMed ID: 3079416
    [No Abstract]   [Full Text] [Related]  

  • 10. Intrapleural administration of cisplatin and etoposide to treat malignant pleural effusions in patients with non-small cell lung cancer.
    Tohda Y; Iwanaga T; Takada M; Yana T; Kawahara M; Negoro S; Okishio K; Kudoh S; Fukuoka M; Furuse K
    Chemotherapy; 1999; 45(3):197-204. PubMed ID: 10224342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
    Radice PA; Bunn PA; Ihde DC
    Cancer Treat Rep; 1979 Aug; 63(8):1231-9. PubMed ID: 225026
    [No Abstract]   [Full Text] [Related]  

  • 12. [Teniposide and cisplatin compared with etoposide and cisplatin for treatment of small cell lung cancer].
    Fan Y; Huang ZY; Zhang YP; Sun L
    Ai Zheng; 2002 Dec; 21(12):1368-71. PubMed ID: 12520751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between VP 16 and VM 26 in Lewis lung carcinoma of the mouse.
    Colombo T; Broggini M; Vaghi M; Amato G; Erba E; D'Incalci M
    Eur J Cancer Clin Oncol; 1986 Feb; 22(2):173-9. PubMed ID: 3699080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anaphylactic reactions to teniposide.
    Siddall SJ; Martin J; Nunn AJ
    Lancet; 1989 Feb; 1(8634):394. PubMed ID: 2563558
    [No Abstract]   [Full Text] [Related]  

  • 15. Podophyllotoxins for brain metastases of small cell lung cancer.
    Haaxma-Reiche H; Berendsen HH; Postmus PE
    J Neurooncol; 1988 Nov; 6(3):231-2. PubMed ID: 2852221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of teniposide in advanced breast cancer.
    Boas J; Rasmussen D; Hansen OP; Engelholm SA; Dombernowsky P
    Cancer Chemother Pharmacol; 1990; 25(6):463-4. PubMed ID: 2311176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of etoposide after intrathoracic instillation to lung cancer patients with pleural effusion.
    Wada I; Yokouchi M; Saitoh H; Takada M; Nakabayashi T; Mino K; Honma T; Takeda T; Hirano K
    Int J Clin Pharmacol Ther; 1999 May; 37(5):254-9. PubMed ID: 10363625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung.
    Roed H; Vindelov LL; Christensen IJ; Spang-Thomsen M; Hansen HH
    Cancer Chemother Pharmacol; 1987; 19(1):16-20. PubMed ID: 3815721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacology and schedule dependency of the podophyllotoxin derivatives.
    Clark PI
    Semin Oncol; 1992 Apr; 19(2 Suppl 6):20-7. PubMed ID: 1411635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the anticancer drugs etoposide (VP 16-213) and teniposide (VM 26) by high-performance liquid chromatography with fluorescence detection.
    Strife RJ; Jardine I; Colvin M
    J Chromatogr; 1981 Jun; 224(1):168-74. PubMed ID: 7263816
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.